The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Open accessAbstract
We have generated a novel transgenic mouse model on a C57BL/6J genetic background that coexpresses KM670/671NL mutated amyloid precursor protein and L166P mutated presenilin 1 under the control of a neuron-specific Thy1 promoter element (APPPS1 mice). Cerebral amyloidosis starts at 6-8 weeks and the ratio of human amyloid (A)beta42 to Abeta40 is 1.5 and 5 in pre-depositing and amyloid-depositing mice, respectively. Consistent with this ratio, extensive congophilic parenchymal amyloid but minimal amyloid angiopathy is observed. Amyloid-associated pathologies include dystrophic synaptic boutons, hyperphosphorylated tau-positive neuritic structures and robust gliosis, with neocortical microglia number increasing threefold from 1 to 8 months of age. Global neocortical neuron loss is not apparent up to 8 months of age, but local neuron loss in the dentate gyrus is observed. Because of the early onset of amyloid lesions, the defined genetic background of the model and the facile breeding characteristics, APPPS1 mice are well suited for studying therapeutic strategies and the pathomechanism of amyloidosis by cross-breeding to other genetically engineered mouse models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activated microglia surround amyloid plaques in the brains of both human patients with AD and mouse models of Aβ amyloidosis13,15,21,22.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although a previous report demonstrated no sex-dependent differences in Aβ accumulation in this APPPS1–21 mouse model13”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A previous report demonstrated no sex-dependent difference in the phenotypes of APP(Swe)/PS1(L166P) mice8.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reactive gliosis, encompassing microgliosis and astrogliosis, are prevalent neuropathological hallmarks observed in the brains of both human AD and mouse models of Aβ amyloidosis8,15,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because it has been known that there is no sex effect in this experimental group8, male and female mice were combined for statistical analyses.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sample sizes were chosen based on prior publications using the APP/PS1 and P301S mouse models, which provided estimations of expected effect sizes and variance.”
From APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints (2023) · cites this paper as Radde et al., 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The APPPS1-21 (APPPS1) mouse line coexpresses human amyloid precursor protein harboring the K670M/ N671L familial AD mutation and presenilin 1 harboring the L166P familial AD mutation, under the control of the neuron-specific Thy1 promoter.21”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APPPS1 mouse line coexpresses APP K670M/N671L and PS1 L166P mutations under the control of the neuronspecific Thy1 promoter and exhibits early and robust A deposition beginning at 6 -8 weeks of age in the cortex and 3-4 months of age in the hippocampus.21”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“dozens of mouse lines overexpressing several combinations of APP and PSEN1 mutations have been created to accelerate the onset of Aβ pathologies in brains [28–30].”
From Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer’s disease (2019) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The APPPS1–21 mouse model used in our study starts to accumulate Aβ in the neocortex at approximately 6 to 8 weeks of age and exhibits robust Aβ accumulation and plaque deposition at 4 months of age13.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Abnormal activation of microglia and astrocytes is observed in the brains of AD patients15 and APPPS1–21 transgenic model mice13.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid-associated gliosis is consistently observed in the brains of AD patients15 and amyloidosis mouse models8,16.”
From Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of Aβ amyloidosis (2024) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“APPPS1-21 mice overexpress a human APP with a Swedish mutation (KM670/671NL) and mutant PS1 with the L166P mutation.”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Radde et al., 2006
The cited source says what the claim attributes to it.
In the citing paper
“During submission of this manuscript, another study (Takalo et al. 2025), using the APP/PS1 model which develops an elevated Aβ42:40 (~5:1) (Radde et al. 2006), proposed that the protective variant reduced the number of plaques and overall plaque load”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Radde et al. 2006
The cited source says what the claim attributes to it.
In the citing paper
“we mated Cx3cr1 knockout mice to two different mouse models of AD that exhibit either rapid deposition of primarily A42 (the APPPS1 model) 21 or gradual deposition of primarily A40 (the R1.40 model).[22][23][24]”
From CX3CR1 Deficiency Alters Microglial Activation and Reduces Beta-Amyloid Deposition in Two Alzheimer's Disease Mouse Models (2010) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“The increased levels of CH25H mRNA and protein were also observed in the frontal cortex of 4-month-old APPPS1-21 mice bearing amyloid plaques [65] (Fig. 1c, d, e).”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [65]
In the citing paper
“the study utilized APP/PS1 and APP23 transgenic mouse models, both of which were generated through expression of mutated PS1 and/or APP under the neuron-specific Thy1 promoter element [151, 152].”
From Microglial dysfunction in brain aging and Alzheimer's disease (2014) · cites this paper as [151]
In the citing paper
“The other major limitation of these mouse models was that while some showed evidence of localized hyperphosphylated tau that may represent “pretangles”[107, 118, 151, 159], none developed neurofibrillary tangles.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Self-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics
Selkoe, D. J., & Schenk, D. (2003) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140248 · Cited by 829
IRIZARRY, M. C., MCNAMARA, M., FEDORCHAK, K., HSIAO, K., & HYMAN, B. T. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199709000-00002 · Cited by 649
Microglial response to amyloid plaques in APPsw transgenic mice.
Frautschy, S. A., Yang, F., Irrizarry, M., Hyman, B. T., Saido, T. C., Hsiao, K., & Cole, G. M. (1998) · Europe PMC (PubMed Central) · Cited by 592
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 565
Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease
Rouleau, I., Salmon, D. P., Butters, N., Kennedy, C. M., & McGuire, K. (1992) · Brain and Cognition · doi:10.1016/0278-2626(92)90112-y · Cited by 556
Neuron loss in APP transgenic mice
Calhoun, M. E., Wiederhold, K.-H., Abramowski, D., Phinney, A. L., Probst, A., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., & Jucker, M. (1998) · Nature · doi:10.1038/27351 · Cited by 502
Self-citation
Cited by
Sorted by citations
Items 801–900 of 1,000
Chaigneau, T., Sha, S., Roux, C. M., Aïd, S., Faucher, A., Chantran, Y., Dorothée, G., & Krantic, S. M. (2025) · Glia · doi:10.1002/glia.70029 · Cited by 3
Animal models for Alzheimer's disease – the industry perspective
Czech, C., & Grueninger, F. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2013.07.001 · Cited by 3
Self-citationBrunner, D., Flunkert, S., Neddens, J., Duller, S., Scopes, D. I. C., Treherne, J. M., & Hutter‐Paier, B. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.09.028 · Cited by 3
Assessment of Social Transmission of Food Preferences Behaviors
der Jeugd, A. V., & D’Hooge, R. (2018) · Journal of Visualized Experiments · doi:10.3791/57029 · Cited by 3
Glycodendrimers as Potential Multitalented Therapeutics in Alzheimer’s Disease
Klementieva, O. L. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88974 · Cited by 3
Tau- but not Aß -pathology enhances NMDAR-dependent depotentiation in AD-mouse models
Faldini, E., Ahmed, T., Buée, L., Blum, D. L., & Balschun, D. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0813-4 · Cited by 3
Mosser, S., Gerber, H., & Fraering, P. C. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15143 · Cited by 3
Cojocaru, A., Rotaru-Zăvăleanu, A. D., Călina, D. C., Gheonea, D. I., Osiac, E., Boboc, I. K. Ş., & Mitran, S. I. (2021) · Europe PMC (PubMed Central) · doi:10.12865/chsj.47.02.17 · Cited by 3
Applications of Induced Pluripotent Stem Cell-Derived Glia in Brain Disease Research and Treatment
Yang, Z., Gong, M., Yang, C., Chen, C., & Zhang, K. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_697 · Cited by 3
FORMINg a link between PTSD and AD
Gräff, J. (2017) · The EMBO Journal · doi:10.15252/embj.201798013 · Cited by 3
Animal Models of Alzheimer's Disease
Bharadwaj, P. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch10 · Cited by 3
Salta, E., Walgrave, H., Balusu, S., Eynden, E. V., Snoeck, S., Craessaerts, K., Thrupp, N., Wolfs, L., Horré, K., Fourne, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.12.988709 · Cited by 3
The Oxytocin Puzzle: Unlocking Alzheimer’s Disease
Sellés, M. C., & Oliveira, M. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231127 · Cited by 3
Liu, X., Sun, C., Dai, Y., Duan, F., He, T., Zhen, M., Liang, E., Zhang, S., Xia, Y., Hu, N., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1620784 · Cited by 2
Buchanan, R. A., Kramer, A. T., Calipari, E. S., Bowman, A. B., Nobis, W. P., & Harrison, F. E. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70821 · Cited by 2
Amyloid‐β Seeds in Alzheimer's Disease: Research Challenges and Implications
Beschörner, N., Xu, Y., Jucker, M., & Ruiz‐Riquelme, A. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70267 · Cited by 2
Self-citationRathod, S., & Agrawal, Y. O. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70317 · Cited by 2
Spiezio, A. D., & Zonta, M. (2026) · Biomolecules · doi:10.3390/biom16030404 · Cited by 2
Decoding the mechanisms of amyloid-β in synaptic toxicity
Toruński, P., Pizzirusso, G., Winblad, B. G., & Arroyo‐García, L. E. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261424292 · Cited by 2
Delaney, H. J., Islam, S., Healy, D., Oglesby, R., Konda, M., Rietman, G. M., Lynch, R., Nazmi, A., Murray, J. T., Cunningham, M. O., et al. (2026) · Brain · doi:10.1093/brain/awag147 · Cited by 2
Clay, K. B., Medlock-Lanier, T., GRIMES, R. N., Oke, O. O., Hudson, B. T., Wilson, M. M., Filipov, N. M., & Roberts-Galbraith, R. H. (2026) · Nature Communications · doi:10.1038/s41467-026-76397-4 · Cited by 2
Leitgeb, R. A. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6810-7_12 · Cited by 2
Zheng, X., & Du, Y. (2021) · Journal of Acupuncture and Tuina Science · doi:10.1007/s11726-021-1239-7 · Cited by 2
Baron, T., Arsac, J.-N., Verchère, J., Tlili, H., Aufauvre, C., & Bétemps, D. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02410-x · Cited by 2
Alzheimer’s Disease from Modeling to Mechanism Research
Sun, X., & Zhang, W. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69188-1_7 · Cited by 2
Role of branched chain amino acid metabolism on aging
Wang, Z., Yu, S., Du, X., Yan, X., & Xin, Y. (2025) · Biogerontology · doi:10.1007/s10522-025-10309-9 · Cited by 2
Girardi, C. S., Yi, L., Fitz, N. F., Gelain, D. P., Lefterov, I. M., & Koldamova, R. P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052435 · Cited by 2
Alzheimer model 5xfad mice and applications to dementia
Ayabe, T., & Ano, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00052-9 · Cited by 2
Choi, G.-E. (2018) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2018.24.4.305 · Cited by 2
Calcium channels linked to altered cellular function and disease
Mader, T., Liu, Z., & Lanner, J. T. (2020) · Current Opinion in Physiology · doi:10.1016/j.cophys.2020.07.010 · Cited by 2
Shivakumar, A. B., Mehak, S. F., Kumari, S., Saraf, V., & Gangadharan, G. (2022) · Springer eBooks · doi:10.1007/978-981-19-1352-5_14 · Cited by 2
Hanssen, K. S., Witter, M. P., Sandvig, A., Sandvig, I., & Kobro‐Flatmoen, A. (2023) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2023.109840 · Cited by 2
Graham, W. V., Bonito-Oliva, A., Agostinelli, R., Karim, R., Deguzman, J., Kelleher, K. S., Petro, M., Lindström, A.-K., Graff, C., Wood, K. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/558809 · Cited by 2
Social isolation impacts late-life socio-cognitive decline in APP/PS1 micePreprint
Rens, E., D’Hooge, R., & der Jeugd, A. V. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/777441 · Cited by 2
Freitag, K., Sterczyk, N., Obermayer, B., Schulz, J., Houtman, J., Fleck, L., Braeuning, C., Sansevrino, R., Hoffmann, C., Milovanović, D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.28.466219 · Cited by 2
Multi-scale Assessment of Brain Blood Volume and Perfusion in the APP/PS1 Mouse Model of AmyloidosisPreprint
Munting, L. P., Derieppe, M., Voortman, L. M., Khmelinskii, A., Suidgeest, E., Hirschler, L., Barbier, E., de Senneville, B. D., & van der Weerd, L. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.01.498298 · Cited by 2
Gildenblat, J., Stamnas, J., & Pahnke, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.12.675752 · Cited by 2
Bevan, R. J., Maguire, E., Mackinnon, E., Salis, E., Phillips, T., Simonazzi, E., Vassileva, M., Allen, N. D., Williams, J., & Taylor, P. R. (2026) · Glia · doi:10.1002/glia.70192 · Cited by 1
Vidal, R., & Ghetti, B. F. (2012) · Prion · doi:10.4161/pri.21023 · Cited by 1
Self-citationFulopova, B., Bennett, W. R., Summers, B. S., Stuart, K. E., King, A. E., Vickers, J. C., & Canty, A. J. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.007 · Cited by 1
(2022) · Journal of Neurology and Experimental Neuroscience · doi:10.17756/jnen.2022-096 · Cited by 1
Generation of sophisticated Alzheimer’s disease mouse models and research advances utilizing them
Hashimoto, S., & Saido, T. C. (2023) · Translational and Regulatory Sciences · doi:10.33611/trs.2023-003 · Cited by 1
Amyloid β–dependent neuronal silencing through synaptic decoupling
Zhang, Y., Chen-Engerer, H.-J., Zhang, K., Zott, B., Varga, Z., Chen, Y., Chen, X., Hongbo, J., Sakmann, B. J., Nelken, I., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2515113122 · Cited by 2
Belyaev, G. P., Petrov, K. A., Semenov, V. E., & Zueva, I. V. (2025) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-025-06493-w · Cited by 1
Mullins, C. A., Gannaban, R. B., Kramer, A., Shah, H., Haque, Z. F., Ramezan, M., Dehghani, F., Palaniyappan, A., Bowers, F., MohanKumar, S. M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251389236 · Cited by 1
Dosseto, A., Tonge, K., & Karl, T. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05480-6 · Cited by 1
Böck, D., Tidecks, L., Wilhelm, M., ElGrawani, W., Duss, S. N., Trevisan, C., Vena, D. L., Reuss, A. M., Kissling, L., Ranucci, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65964-w · Cited by 1
CDK3 induces neuronal death and brain atrophy in Alzheimer’s disease
Zhuang, K., Zi, L., Su, X., Chen, H., Li, X., Wang, S., Xia, Y., Wu, B., Su, Y., Chen, S., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-01026-6 · Cited by 1
Pyk2 plays a critical role in synaptic dysfunction during the early stages of Alzheimer’s disease
Rodriguez, Q., Payet, F., Vargas-Baron, K., Borel, E., Lanté, F., Boisseau, S., Blot, B., Girault, J., & Buisson, A. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00021-4 · Cited by 1
Modeling diseases of aging in larval zebrafish, a paradoxical yet powerful strategy
Özcan, G. G., & Rihel, J. (2026) · Genetics · doi:10.1093/genetics/iyag027 · Cited by 1
Early Müller Glial Activation and Retinal Ganglion Cell Synaptic Dysfunction in APP/PS1 Mice
Zhou, Y., Qi, G., Zhou, H., Gong, P., Wang, Z., Song, X., Tian, C., Wu, H., & Qin, S. (2026) · Cells · doi:10.3390/cells15090801 · Cited by 1
Cruz-Sesé, J., Miron-Alcala, M., Alfonso-Triguero, M., Olalde, J., Ruiz, L., Galbis-Gramage, N., Cortés, L., Escobar, L., Preman, P., Snellinx, A., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117803 · Cited by 1
Zhu, X., Haure‐Mirande, J., Bicak, M., Dong, P., Kruglikov, I., Li, A., Al‐subaie, A., Fossati, V., Noggle, S., Gandy, S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71684 · Cited by 1
Fecal ATX(N) profiling reveals early genotype-associated molecular signatures in APP/PS1 mice
Seignobos, M., Boisseau, S., Vossier, F., Rauzier, L., Buisson, A., & Jacquier‐Sarlin, M. R. (2026) · Scientific Reports · doi:10.1038/s41598-026-72937-6 · Cited by 1
Pathological Validation of Animal Models of Dementia
Pirici, D. N., Broeckhoven, C. V., & Kumar‐Singh, S. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_7 · Cited by 1
Immunopathology of the Nervous System
Remick, A. K., Pershing, M. L., Papenfuss, T. L., Lanigan, L. G., Beck, M. J., & Toot, J. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-47385-7_5 · Cited by 1
van, T., Kadish, I., Funke, S. A., & Willbol, D. (2011) · InTech eBooks · doi:10.5772/24282 · Cited by 1
Roh, J. H., & Holtzman, D. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809813-4.00007-7 · Cited by 1
Sex differences in Alzheimer’s disease animal models
Ippati, S., Ittner, L. M., & Ke, Y. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819344-0.00003-x · Cited by 1
Assessment of the Alzheimer progression with multiwavelength Stokes polarimetry
Borovkova, M. A., Sieryi, O., Pahnke, J., Bykov, A., & Meglinski, I. V. (2021) · Translational Biophotonics: Diagnostics and Therapeutics · doi:10.1117/12.2614594 · Cited by 1
Képes, Z., Barkóczi, A., Szabó, J. P., Kálmán-Szabó, I., Arató, V., Jószai, I., Deák, Á., Kertész, I., Hajdu, I., & Trencsényi, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213950 · Cited by 1
Feng, N.-N., Li, L., Liu, L.-Z., He, R.-B., Xian, X., Liu, L.-R., Hu, Y.-Y., & Li, W. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110600 · Cited by 1
Genetic Signaling in Glioblastoma Multiforme (GBM): A Current Overview
Lukiw, W. J., & Culicchia, F. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_24 · Cited by 1
Shah, D., Jonckers, E., Praet, J., Vanhoutte, G., y Palacios, R. D., Bigot, C., D’Souza, D. V., Verhoye, M., & der Linden, A. V. (2014) · PLoS ONE · doi:10.1371/annotation/5bfdca66-ef38-403a-a370-9c273d878e4a · Cited by 1
SERF deletion modifies amyloid aggregation in a mouse model of Alzheimer’s diseasePreprint
Stroo, E., Janssen, L., Sin, O., Hogewerf, W., Koster, M. H., Harkema, L., Youssef, S. A., Beschörner, N., Wolters, A. H. G., Bakker, B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.05.423442 · Cited by 1
Self-citationSchieb, H. (2011) · DuEPublico (University of Duisburg-Essen)
Microglial properties in health and disease
Krabbe, G. (2011) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-15999
Hölscher, C. (2012) · Wiley eBooks · doi:10.1002/9781118185537.ch10
Self-citationAmyloid precursor protein with the Alzheimer´s disease 670/671 mutation : Animal and cellular models
Kloskowska, E. (2008) · Figshare
Glial cell reactivity in mouse models reflecting different aspects of Alzheimer's disease
Behrendt, M. G. (2012) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.14767
Sarlus, H. (2015) · Figshare
Neurotransmitter and neurohormone receptors on microglia
Pannell, M. (2014) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-16079
Hölscher, C. (2011) · InTech eBooks · doi:10.5772/18372
Self-citationReview: prion protein and amyloid beta interactions
Minikel, E. V. (2013)
Leitgeb, R. A., Lasser, T., & Villiger, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-06419-2_30
Dynamics of amyloid plaque formation in Alzheimer’s Disease
McCarter, J. F. (2014) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.17434
Bone Marrow-Derived Cell Accumulation in the Brain in a Murine Model of Alzheimer’s Disease
Barr, C. (2013) · Summit (Simon Fraser University)
Using TUDCA to treat Alzheimer's disease after pathology onset in APP/PS1 mice
Dionísio, P. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Aggregation-Promoting Factors in Neurodegenerative Diseases - Insights from a C. elegans Model
Sin, O. M. A. F. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/qbyj-gk59
Using TUDCA to treat Alzheimer's disease after pathology onset in APP/PS1 mice
Farmácia, F. D. (2014)
Imaging mouse models of neurodegeneration using multi-parametric MRI
Holmes, H. (2015) · UCL Discovery (University College London)
Princz-Kranz, F. L. (2010) · Zurich Open Repository and Archive (University of Zurich) · doi:10.3929/ethz-a-006097535
Unspecific binding of cRNA probe to plaques in two mouse models for Alzheimer’s disease
Molecular Anatomy and Dysfunction of Mouse Development Group, Schaarschuch, A., Redies, C., & Hertel, N. (2016) · Journal of Negative Results in BioMedicine · doi:10.1186/s12952-016-0065-9
Bosson, A. (2016) · theses.fr (ABES) · doi:10.70675/7a434986zad6az439ezbc56z26ed9ad63653
Menéndez, E. Q. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Metaplasticity Tunes Functional Plasticity in the Rodent Hippocampus
Li, Q. (2015) · Digitale Bibliothek Braunschweig (Verbundzentrale Göttingen (VZG)) · doi:10.24355/dbbs.084-201503260942-0
Pihlaja, R., Lindgrén, N., Torittu, A., Snellman, A., Haaparanta‐Solin, M., & Rinne, J. O. (2018) · World Journal of Neuroscience · doi:10.4236/wjns.2018.82014
Altered adult neurogenesis in a mouse model of human tauopathy
Komuro, Y. (2015) · OhioLink ETD Center (Ohio Library and Information Network)
Histologie sérielle afin d'étudier les changements de microvasculature dans la maladie d'Alzheimer
Delafontaine-Martel, P. (2018) · PolyPublie (École Polytechnique de Montréal)
Morelli, A. M., Migliorino, M. R., Morabito, A., Chiari, R., Grossi, F., Bordi, P., Costanzo, F. D., Delmonte, A., Romano, G., Misino, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy292.026
Impact du VEGF sur les altérations synaptiques dans la maladie d’Alzheimer
Martin, L. (2018) · theses.fr (ABES) · doi:10.70675/e24b560ez70e5z4840z9195zde9043132aa0
Ast, A. (2019) · Refubium (Universitätsbibliothek der Freien Universität Berlin) · doi:10.17169/refubium-4035
Hanssen, K. S. (2019) · NORA - Norwegian Open Research Archives
Metadata
- Authors
- Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., Haass, C., Ghetti, B., Czech, C., Hölscher, C., Mathews, P. M., & Jucker, M.
- Affiliations
- Hertie Institute for Clinical Brain Research (DE)
- University of Basel (CH)
- University of Tübingen (DE)
- University of Ulster (GB)
- Adolf-Butenandt-Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie (DE)
- Indiana University School of Medicine (US)
- F. Hoffmann-La Roche AG (CH)
- New York University (US)
- Corresponding author
- Jucker, Mathias
- ORCID
- Venue
- The EMBO Reports
- Published
- 2006-08-11
- Volume
- 7
- Issue
- 9
- Pages
- 940-946
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- PMC
- PMC1559665
- OpenAlex
- W2156788921
- Cited by
- 986
- References
- 32
- Citations by year
- 2026: 33 · 2025: 60 · 2024: 75 · 2023: 85 · 2022: 73 · 2021: 86 · 2020: 93 · 2019: 79 · 2018: 58 · 2017: 41 · 2016: 46 · 2015: 41 · 2014: 36 · 2013: 50 · 2012: 37
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- EMBO Reports (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Funders
- European Commission (LSHM-CT-2003-503330)
- Boehringer Ingelheim Stiftung
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- cerebral amyloidosis, amyloid-beta 42, amyloid angiopathy, tau hyperphosphorylation, gliosis, microglia, Alzheimer's disease model
- MeSH terms
- Animals, Cognition, Disease Models, Animal, Inflammation, Male, Membrane Proteins, Mice, Inbred C57BL, Mice, Transgenic, Neurons, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Cerebral Amyloid Angiopathy, Neocortex, Mice, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
